Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Retatrutide and tirzepatide both act on GLP-1 and GIP receptors - they overlap heavily on the same pathways
Prior studies examining individual agents reported SGLT-2 inhibitor monotherapy to be associated with a 2029% reduction in CRC risk versus other antidiabetic agents [10,11,12,13,14,15], and GLP-1 RA monotherapy to be associated with a 2330% reduction [18, 19]
Future investigations should address chronic exposure, long-term retention, neurotoxicity, and standardised reporting to ensure safe clinical translation
Lifestyle interventions reduce anxiety severity alongside medication adjustment: consistent sleep (7-9 hours), limiting caffeine intake, practicing grounding techniques like 4-7-8 breathing, and 20-30 minutes of daily cardio or yoga
Presented for research literature review only Udenigwe CC et al
US$ 29.44
US$ 26.88
US$ 20.84
US$ 22.29
